Entries by LRuas

Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program

/in

Amsterdam and San Francisco / Houston / Singapore, 4 January 2023 — Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, and Hummingbird Bioscience (Hummingbird Bio), a data-driven precision biotherapeutics company using its Rational Antibody Discovery (RAD) platform to discover and […]

Poolbeg identifies new potential drug candidates for Respiratory Syncytial Virus infections as part of Artificial Intelligence Programme

/in

Collaboration with OneThree Biotech identifies novel RSV treatments First time RSV drug candidates identified using AI Candidates with existing Phase I clinical data packages prioritised to reduce risk Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading infectious disease focused biopharmaceutical company, announces that it has successfully identified potential new drug candidates from […]

2022 | Optimum’s Year in Review

/in ,

It’s nearly the end of 2022! It was an exciting year for Optimum’s clients which demonstrated the resilience and creativity that has made the life sciences industry so successful. We have outlined below a small fraction of the activity that has kept us busy this year: Deal, deals, deals As usual, 2022 was a year […]

Cutting-edge protein design project to join BioInnovation Institute’s Bio Studio program

/in

BioInnovation Institute (BII), an international enterprise foundation with a non-profit objective incubating and accelerating world-class life science research, announces today that it has accepted a new project into its Bio Studio program. Based on recent breakthroughs in Artificial Intelligence (AI) and protein design, the project is creating a new class of therapeutic proteins to modulate […]

© Optimum Strategic Communications.